Global mask sales were weaker than expectations, but we see F18 device and mask growth rebounding.
FY18 revenue is forecast to grow by of 5%+ and underlying EPS growth in the high single digits.
You're not a member! Trial today
RMD is trading at 24x F18 EPS and we see the current sell-off as a buying opportunity.
We need to give this name a wide range to find support and the buying zone is between $8.50 and $9.25. 1, 2 & 3 years out, the stock will be trading at higher prices. Keep an eye out for the next Algo buy signal in RMD!
